TP53 and astrocytoma (excluding glioblastoma): Grades II and III astrocytoma cases from the dataset were analysed for OS and PFS based on TP53 mutation status, and the results mirrored the OS findings from our cohort with TP53 mutant cases, showing significantly increased OS (median survival TP53 WT 30 months vs. TP53 MT 75 months, p < 0.001).